ARTICLE
20 February 2024

FDA Issues Final Rule To More Closely Align With ISO 13485

AP
Arnold & Porter
Contributor
Arnold & Porter is a firm of more than 1,000 lawyers, providing sophisticated litigation and transactional capabilities, renowned regulatory experience and market-leading multidisciplinary practices in the life sciences and financial services industries. Our global reach, experience and deep knowledge allow us to work across geographic, cultural, technological and ideological borders.
On 2 February 2024, the US Food and Drug Administration (FDA) published its much anticipated final rule amending the medical device Quality System Regulation...
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

On 2 February 2024, the US Food and Drug Administration (FDA) published its much anticipated final rule amending the medical device Quality System Regulation, which sets out the FDA's quality management system (QMS) requirements for medical devices. The amendments seek to align more closely with International Standard Organization (ISO) standard 13485:2016, Medical Devices — Quality Management System Requirements for Regulatory Purposes. The ISO standard is the version used in much of the world and provides a good framework for meeting the requirements in the EU Medical Devices Regulation (MDR).

The FDA's decision to align the US QMS requirements to international standards is one of many efforts undertaken by the Agency to promote global regulatory harmonization. Ex-US device and tech developers will hopefully receive some of the efficiency and alignment they were hoping for when it comes to quality system compliance requirements in the US.

You can read more in our advisory.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

ARTICLE
20 February 2024

FDA Issues Final Rule To More Closely Align With ISO 13485

United States Food, Drugs, Healthcare, Life Sciences
Contributor
Arnold & Porter is a firm of more than 1,000 lawyers, providing sophisticated litigation and transactional capabilities, renowned regulatory experience and market-leading multidisciplinary practices in the life sciences and financial services industries. Our global reach, experience and deep knowledge allow us to work across geographic, cultural, technological and ideological borders.
See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More